I never said the results were more of the same. I think it may have been F1ash who made a post, with links, showing other drugs also had a beneficial impact in earlier trials.
It looks good on paper but have not been received well. So they completed enrollment for next trial.
Most of the drugs that reached P2 or P3 showed promising results in early stages - the companies were too excited about them same way AVXL is.
Well how much one can get excited about inconclusive results about 25 patient trial ?
This is not like a cancer drug that shows very high tumor shrinkage in P1 which is conclusive evidence not a graph that one tries to split to get evidence.
News 
Market Data 
Discover 
